Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Denali Therapeutics Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Takeda Pharmaceutical terminated its collaboration agreement with Denali Therapeutics for the DNL593 program effective 60 days from April 3, 2026, with all rights reverting to Denali and no further financial obligations. This strategic decision removes a major partnership but eliminates future payment obligations and restores full control of the asset to Denali.
Key Takeaways
Takeda initiated termination of the January 3, 2018 Collaboration Agreement for DNL593 co-development and co-commercialization
All intellectual property rights to DNL593 revert to Denali upon termination effective 60 days from notice date
2 more takeaways
Related Filings (4)
4 more filings from Denali Therapeutics Inc. in the last 90 days